The market capitalization or net corporate worth of LENZ Therapeutics fluctuates dynamically with daily trading sessions on the Nasdaq exchange, reflecting shifting investor sentiment regarding its commercial product uptake. Total enterprise valuation is driven by its intellectual property portfolio, commercial sales projections for its FDA-approved eye drop, and remaining cash reserves supporting its operational runway.